What is Lucence?
Founded in 2016 and headquartered in Singapore, Lucence operates at the intersection of biotechnology and clinical diagnostics. The company specializes in the development of advanced liquid biopsy blood tests, which provide a non-invasive method for detecting and monitoring cancer. By analyzing circulating tumor DNA and other biomarkers, Lucence enables oncologists to make data-driven decisions regarding therapeutic interventions. This molecular profiling approach is essential for personalized medicine, allowing for the identification of specific genetic mutations that dictate treatment efficacy. As the demand for precision oncology tools rises, Lucence remains at the forefront of the industry, utilizing its robust research and development pipeline to enhance patient care standards globally.
How much funding has Lucence raised?
Lucence has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2019): $20M with participation from Lim Kaling, Heliconia Capital, SGInnovate, Koh Boon Hwee, and IHH Healthcare
Key Investors in Lucence
SGInnovate
SGInnovate is dedicated to growing Singapore's Deep Tech landscape by investing in startups and nurturing talent within the sector.
Heliconia Capital
Heliconia Capital is an investment firm that focuses on growth-stage companies, providing strategic capital to help businesses scale internationally.
Lim Kaling
A prominent private investor known for supporting high-growth technology and healthcare ventures with a focus on long-term value creation.
What's next for Lucence?
With this major enterprise-level funding, Lucence is well-positioned to accelerate its clinical validation studies and expand its commercial footprint in key international markets. The strategic allocation of this capital will likely focus on scaling laboratory operations and enhancing the sensitivity of its diagnostic assays. Furthermore, the company is expected to deepen its collaborations with healthcare providers and pharmaceutical partners to integrate its molecular profiling solutions into standard oncology workflows. As Lucence moves into its next phase of growth, the focus will remain on achieving regulatory milestones and broadening the clinical utility of its liquid biopsy platform, ultimately aiming to improve survival rates through earlier and more accurate cancer detection.
See full Lucence company page
